Chessler Steven D, Lee Donald E
Department of Medicine, University of California Irvine, Irvine, California, USA.
BMJ Case Rep. 2018 Jun 14;2018:bcr-2018-225358. doi: 10.1136/bcr-2018-225358.
A 29-year-old woman was referred for new-onset diabetes mellitus after her glycosylated haemoglobin (HbA1c) was found to be 10.2%. Three years earlier, the patient's HbA1c-measured by the same clinical laboratory-had been 5.5%. The newer HbA1c was discordant with fasting glucose levels and a lack of diabetes-associated symptoms. The laboratory reported that their assay methodology remained unchanged and also that no haemoglobin variants were detected. Further investigation, however, revealed, first, that the patient carried a haemoglobin alpha chain mutation (Hb Wayne) that can sometimes cause assay interference and, second, that although the laboratory's assay methodology had not changed, their assay instrument had. Depending on assay methodology, haemoglobin variants can cause HbA1c assay interference and the presence of these variants may not be detected by the performing laboratory. Interference may not only be dependent on assay methodology but also on the assay instrument used.
一名29岁女性在糖化血红蛋白(HbA1c)被发现为10.2%后,因新发糖尿病前来就诊。三年前,由同一临床实验室检测的该患者HbA1c为5.5%。此次更新的HbA1c结果与空腹血糖水平及缺乏糖尿病相关症状不符。实验室报告称其检测方法未变,且未检测到血红蛋白变异体。然而,进一步调查发现,首先,该患者携带一种血红蛋白α链突变(Hb Wayne),有时会导致检测干扰;其次,尽管实验室的检测方法未变,但检测仪器更换了。根据检测方法的不同,血红蛋白变异体可能会导致HbA1c检测干扰,而执行检测的实验室可能无法检测到这些变异体的存在。干扰不仅可能取决于检测方法,还可能取决于所使用的检测仪器。